Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 3/20 | 0.63 |
| ▸ | CTSS | P25774 | 4/20 | 0.60 |
| ▸ | PPARG | P37231 | 2/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | SYK | P43405 | 1/20 | 0.54 |
| ▸ | KLK7 | P49862 | 2/20 | 0.50 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 2/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
| ▸ | ACE | P12821 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1000339 | 1.00 | PPARA (0.63) | PPARACTSSPPARGATMSYK | |
| SCHEMBL272967 | 1.00 | PPARA (0.63) | PPARACTSSPPARGATMSYK | |
| SCHEMBL18407225 | 0.92 | PPARA (0.69) | PPARACTSSPPARGATMSYK | |
| SCHEMBL3575301 | 0.90 | PPARA (0.61) | PPARACTSSPPARGATMSYK | |
| SCHEMBL25467757 | 0.88 | PPARA (0.65) | PPARACTSSPPARGATMSYK | |
| SCHEMBL1132570 | 0.88 | PPARA (0.65) | PPARACTSSPPARGATMSYK | |
| SCHEMBL212796 | 0.88 | PPARA (0.65) | PPARACTSSPPARGATMSYK | |
| SCHEMBL27538401 | 0.88 | ATM (0.65) | PPARACTSSPPARGATMSYK | |
| SCHEMBL212797 | 0.88 | PPARA (0.65) | PPARACTSSPPARGATMSYK | |
| SCHEMBL903406 | 0.88 | ATM (0.65) | PPARACTSSPPARGATMSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2007396-B1 | Enfumafungin derivatives as antifungal agents | MERCK SHARP & DOHME (US) | 2013-02-13 | — | — | EP | disclosed |
| US-7863465-B2 | Antifungal agents | MERCK SHARP & DOHME CORP. (US) | 2011-01-04 | — | — | US | disclosed |
| EP-2007396-A1 | ANTIFUNGAL AGENTS | Merck and Co., Inc. (US) | 2008-12-31 | — | — | EP | disclosed |
| US-20080009504-A1 | Antifungal agents | SCYNEXIS, INC. | 2008-01-10 | — | — | US | disclosed |
| WO-2007127012-A1 | ANTIFUNGAL AGENTS | MERCK & CO., INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| EP-1208104-B1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASES | AGOURON PHARMA (US) | 2005-01-19 | — | — | EP | disclosed |
| US-6548494-B1 | 3,4-dihydro-2H-(1,4)diazepino(6,7,1-hi)indol-1-one or 1-thione derivatives where indole C3 could also be N; use treating cancers as well as stroke, head trauma, and neurodegenerative diseases | AGOURON PHARMACEUTICALS, INC. | 2003-04-15 | — | — | US | disclosed |
| EP-1208104-A2 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASES | AGOURON PHARMACEUTICALS, INC. (US) | 2002-05-29 | — | — | EP | disclosed |
| WO-2001016136-A2 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASES | AGOURON PHARMACEUTICALS, INC. (US) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009504-A1 | Antifungal agents | DPM1, MAN2B1, MAN2A1 | PPARA 4684/4885CTSS 554/4885PPARG 4446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.